4.4 Article

Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis

期刊

IMMUNITY INFLAMMATION AND DISEASE
卷 10, 期 1, 页码 93-100

出版社

WILEY
DOI: 10.1002/iid3.546

关键词

incidence; liver transplantation; Pneumocystis jirovecii pneumonia; prophylaxis; trimethoprim sulfamethoxazole

资金

  1. Novo Nordisk Foundation
  2. Independent Research Fund (FSS)
  3. Research Foundation of Rigshospitalet

向作者/读者索取更多资源

This study investigated the incidence rate of PCP and related hospitalization and mortality rates in liver transplant recipients. Results showed that PCP was not detected in liver transplant recipients while on prophylaxis, and all recipients diagnosed with PCP were hospitalized but none died.
Background: Pneumocystis jirovecii pneumonia (PCP) is an opportunistic infection in organ transplant recipients that may be prevented by antibiotic prophylaxis. We aimed to investigate the incidence rate (IR) of PCP and the related hospitalization and mortality rates in liver transplant recipients in an era of routine prophylaxis. Methods: We included all adult liver transplant recipients transplanted at Rigshospitalet between January 1, 2011 and October 1, 2019. Microbiology data were obtained from the Danish Microbiology Database (MiBa), a national database containing all data from all Departments of Clinical Microbiology in Denmark receiving samples from both hospitals and general practices. According to local guidelines, PCP prophylaxis was initiated 1 week post-transplantation and discontinued after 6 months or sooner in patients experiencing side effects. Results: We included 343 liver transplant recipients with 1153 person-years of follow-up (PYFU), of which 269 (78%) received PCP prophylaxis during the first 6 months posttransplantation. Seven (2%) recipients were diagnosed with PCP during follow-up. In the first 6 months posttransplantation and in 269 transplant recipients who received prophylaxis there were zero PCP events while the IR was 32 (95% confidence interval [CI] 2.9-148) per 1000 PYFU in 74 recipient who did not receive prophylaxis. During 7th to 12th month posttransplantation the IR was 20 (95% CI: 5.5-53) per 1000 PYFU. All seven (100%) recipients diagnosed with PCP were hospitalized, however none died. Conclusions: PCP was not detected in liver transplant recipients while on prophylaxis. Though, it worth mentioning that two out of the seven PCP patients received high-dose prednisolone before the PCP event. All liver transplant recipients with PCP were hospitalized, but none died. Randomized clinical trials to determine the optimal duration of prophylaxis are warranted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据